What does your clinician set up before the first injection?
Tirzepatide is a prescription medication. Before your first injection, a licensed clinician reviews your health history, current medications, and weight management goals. For most patients, this involves a brief assessment and labs. The clinician determines whether tirzepatide is appropriate and establishes your starting dose.
The standard starting dose is 2.5 mg weekly. This is the lowest dose in the titration schedule — chosen specifically because it minimizes GI side effects during the body’s initial adaptation period. Starting at a higher dose to accelerate results is not clinically appropriate; the titration schedule is a tool for tolerability management, not caution theater.
Compounded tirzepatide from a licensed 503A pharmacy arrives in vials with your prescribed concentration. Your clinician will walk you through subcutaneous injection technique, injection site rotation, and proper storage before you administer your first dose.
What happens in weeks 1–4, the initiation phase?
The first four weeks are the adaptation period. Here is what the clinical data and patient experience consistently show:
Appetite changes begin quickly
Most patients notice reduced appetite within the first few days of starting tirzepatide. Tirzepatide acts as a dual GLP-1 and GIP receptor agonist. GLP-1 receptor activation slows gastric emptying, reduces appetite signaling, and acts on hypothalamic satiety centers. GIP receptor activation adds to the metabolic effect. The combined result is that food becomes less compelling and fullness arrives earlier than usual.
For some patients, this effect is dramatic from week one. For others, it builds gradually. The physiological response is individual — appetite suppression that feels unremarkable at 2.5 mg often intensifies with dose escalation.
Nausea peaks and subsides
Nausea is the most commonly reported side effect in clinical trials and the most common reason for dose reduction. In the SURMOUNT-1 trial, nausea was reported by approximately 30–45% of participants across dose groups. The good news: it is typically transient.
For most patients, nausea is worst in the 4–24 hours following each injection, particularly in the first 1–2 weeks at a new dose level. As the body adapts to the gastric motility slowing effect, nausea diminishes. By week 3–4 at a stable dose, most patients report significantly less or no nausea.
Practical management: eat smaller meals, avoid high-fat and fried foods, avoid eating close to injection time, and stay hydrated. If nausea is significantly impairing, contact your clinician — dose adjustment or injection timing changes are tools available to you.
Weight change in weeks 1–4
Measurable weight loss typically begins in weeks 2–4, primarily driven by reduced caloric intake from appetite suppression. The initial changes often include some fluid loss alongside early fat loss. Do not anchor expectations to week-1 scale changes — they vary widely and are not predictive of long-term response.
The slow titration isn’t caution theater — starting low and stepping up every four weeks is the tool that keeps early nausea manageable.
What is the tirzepatide titration schedule?
After 4 weeks at 2.5 mg, the standard protocol increases the dose to 5 mg weekly, then at subsequent 4-week intervals to 7.5 mg, 10 mg, 12.5 mg, and finally 15 mg — if needed and tolerated. Your clinician individualizes this schedule based on your response and side-effect burden.
| Weeks | Dose | What to expect |
|---|---|---|
| 1–4 | 2.5 mg/week | Appetite suppression begins; nausea most pronounced in first 1–2 weeks |
| 5–8 | 5 mg/week | First dose increase; some nausea at new dose level, typically milder than initiation |
| 9–12 | 7.5 mg/week | Weight loss often accelerates; GI adaptation improving |
| 13–16 | 10 mg/week | Steepest weight-loss trajectory for most patients |
| 17–20 | 12.5 mg/week | Approaching maintenance; clinician assesses whether further escalation needed |
| 21+ | 15 mg/week (max) | Maintenance dose if tolerated; many patients maintain at 10–12.5 mg |
Dosing is always individualized by your clinician based on response and tolerance.
Expect some nausea at each dose increase
The GI adaptation experience repeats at each dose escalation, typically milder than at initiation. Most patients find that side effects at each new dose are less pronounced than at their first injection, as the body has already begun adapting to tirzepatide’s mechanism. But significant individual variation exists — some patients tolerate dose escalation easily, others require a slower titration schedule.
Weight loss accelerates
The titration phase is when most patients see their most significant rate of weight loss. In the SURMOUNT-1 trial, participants continued to lose weight through week 36 and beyond, with the steepest trajectory in the months following dose escalation. Cumulative weight loss at 72 weeks for the 15 mg dose group averaged approximately 20–22% of body weight.
These are trial averages across large populations — individual results differ. Body composition, baseline metabolic health, dietary adherence, and activity all influence the response.
Check-ins and labs
Most clinicians schedule check-ins at 4–8 week intervals during titration. These serve two purposes: monitoring for adverse effects and adjusting the dose schedule, and reviewing response to confirm the protocol is working. Some clinicians order follow-up labs (metabolic panel, lipids) at the 8–12 week mark to observe downstream metabolic changes.
What happens in months 3–6 as you build toward maintenance?
By months 3–6, most patients have reached their maintenance dose and GI side effects have largely resolved. The appetite suppression effect has become predictable and manageable. Many patients describe this as the phase where tirzepatide starts to feel “normal” rather than effortful.
Weight loss continues through this phase, though the rate typically slows compared to the early titration months. This is physiologically expected — as body weight decreases, total daily energy expenditure decreases, and the caloric deficit narrows. Adjusting dietary composition and activity during this phase helps sustain the trajectory.
What side effects should you watch for and report to your clinician?
- Severe or persistent nausea and vomiting: Mild transient nausea is expected. Vomiting that prevents hydration or nutrition for more than 24 hours warrants contact with your clinician.
- Abdominal pain: Severe, persistent abdominal pain — particularly if radiating to the back — should be reported promptly. Pancreatitis is a rare but recognized risk with GLP-1 receptor agonists.
- Signs of dehydration: Vomiting and diarrhea can cause dehydration. Dizziness, dark urine, and marked fatigue should prompt increased fluid intake and clinical contact if severe.
- Rapid pulse or heart rate changes: GLP-1 receptor agonists have been associated with modest increases in resting heart rate in some patients. Significant or symptomatic increases warrant clinical review.
Frequently asked questions
What happens when you first start tirzepatide?
Most people notice reduced appetite within the first week. Nausea is the most common early side effect, typically mild to moderate and most pronounced in the first 1–2 weeks at each new dose level. Your clinician will start you at the lowest dose (usually 2.5 mg weekly) and titrate up slowly to minimize this.
How long does it take for tirzepatide to start working?
Appetite suppression typically begins in the first week. Measurable weight change usually appears within 2–4 weeks. Significant results accumulate over months — the SURMOUNT trials showed progressive weight loss through 72 weeks, with the largest losses occurring between months 3 and 9 for most participants.
What is the tirzepatide titration schedule?
The standard titration schedule starts at 2.5 mg weekly for 4 weeks, then increases by 2.5 mg every 4 weeks as tolerated, up to a target maintenance dose of 5–15 mg weekly. Your clinician determines your maintenance dose based on your response and tolerance. Doses are always individualized.
What are the most common side effects when starting tirzepatide?
Nausea is the most common, reported by roughly 30–45% of participants in clinical trials at various dose levels. Vomiting, diarrhea, constipation, and decreased appetite are also frequently reported. Most GI side effects are dose-dependent and transient, peaking during dose escalation and subsiding at stable dose.
Can I eat normally when starting tirzepatide?
Tirzepatide significantly slows gastric emptying. Eating smaller, more frequent meals and avoiding high-fat or very spicy foods — particularly in the early weeks — reduces nausea. Your clinician will provide dietary guidance tailored to your starting dose and GI tolerance.
How do I know if tirzepatide is working?
The primary indicator is progressive weight change over weeks and months. Secondary indicators include reduced hunger, improved appetite control, and changes in relevant metabolic labs if monitored. Your clinician will typically review your response at 4–8 week check-ins during the titration phase.